MedTrace Logo

Solifenacin Succinate 5mg or 10mg Once Daily in the Treatment of Urgency Symptoms

NCT00801944 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 973

Last updated 2014-09-18

No results posted yet for this study

Summary

Prospective, double-blind, double-randomised, 2-arm parallel group study. Optimal dose increase. Primary efficacy assessment of OAB symptoms by patient diaries.

Conditions

  • Urinary Bladder, Overactive

Interventions

DRUG

Solifenacin succinate

oral

DRUG

Placebo

oral

Sponsors & Collaborators

  • Astellas Pharma Inc

    lead INDUSTRY

Principal Investigators

  • Central Contact · Astellas Pharma Europe B.V.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-04-30
Primary Completion
2005-10-31
Completion
2005-10-31

Countries

  • Belgium
  • Czechia
  • Egypt
  • France
  • Germany
  • Greece
  • Hungary
  • Italy
  • Poland
  • Portugal
  • Russia
  • Slovakia
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00801944 on ClinicalTrials.gov